Skip to content

Initial prostate biopsy: 12 versus 20 cores - prospective study

20 core transrectal prostate biopsy is the initial approach of choice in a selected group of patients with suspected prostate adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-4dkhh3
Enrollment
Unknown
Registered
2018-01-29
Start date
2014-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm of prostate

Interventions

Twelve core group (105 participants): transrectal ultrasound guided prostate biopsy, after troncular bilateral anesthesia with 10 ml of 1% lidocaine, using a 7.5 Hz probe, an 18-gauge trucut needle, a
Procedure/surgery
E01.370.225.500.384.100.370
Z12.5

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Fundação de Apoio à Universidade Federal de São Paulo
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Patients referred for a prostate biopsy with suspected prostate cancer: positive digital rectal exam findings and/or elevated serum prostatic-specific antigen levels.

Exclusion criteria

Exclusion criteria: Previous prostate biopsy and/or prostatic-specific antigen greater than 20 ng/ml

Design outcomes

Primary

MeasureTime frame
Higher prostate cancer detection rate using a 20-core biopsy protocol than the standard 12-core biopsy protocol, based on the histological analysis of cores.

Secondary

MeasureTime frame
Higher clinically insignificant prostate cancer detection rate using a 20-core biopsy protocol than the standard 12-core biopsy protocol, based on the histological analysis of cores. Clinically insignificant cancers: maximum of three positive cores, greatest percentage of cancer of 50% of core length, and Gleason score of 6 or less. ;Higher prostate cancer detection rate using a 20-core biopsy protocol than de standard 12-core biopsy protocol, based on the histological analysis of cores in patients with prostatic-specific antigen lower than 6 ng/ml, prostatic volume lower than 40 cm³ and/or younger than 60 years old.

Countries

Brazil

Contacts

Public ContactRaphael Sandes Solha

Universidade Federal de São Paulo

r_solha@hotmail.com+55-11-55764848

Outcome results

None listed

Source: REBEC (via WHO ICTRP)